Headlines about Anika Therapeutics (NASDAQ:ANIK) have been trending positive on Friday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anika Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.959962915856 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Global hemostats market estimated to grow at a CAGR of 6.6% by 2024 (whatech.com)
- Facial Wrinkle Treatment Market Undertake Strapping Growth During 2017 – 2025 (sbwire.com)
- Facial Rejuvenation Market Size to Record a CAGR of 4.9% by 2021 (medgadget.com)
- Surgical Mesh Pipeline Assessment 2017 (medgadget.com)
- Combination Treatments for Scars Market Significant Profits Estimated to be Generated by 2025 (mynewsdesk.com)
A number of research firms recently issued reports on ANIK. Zacks Investment Research raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday.
Anika Therapeutics (NASDAQ ANIK) traded up 0.66% during mid-day trading on Friday, reaching $51.72. The company had a trading volume of 87,125 shares. The firm has a market capitalization of $758.11 million, a P/E ratio of 22.98 and a beta of 1.69. The firm’s 50-day moving average is $49.30 and its 200-day moving average is $47.05. Anika Therapeutics has a one year low of $41.38 and a one year high of $53.99.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The firm had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. During the same period in the previous year, the firm earned $0.57 earnings per share. The company’s revenue was up 25.9% compared to the same quarter last year. On average, equities research analysts anticipate that Anika Therapeutics will post $2.00 earnings per share for the current fiscal year.
In other news, CEO Charles H. Sherwood sold 63,799 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the transaction, the chief executive officer now directly owns 174,705 shares of the company’s stock, valued at $8,873,266.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffery S. Thompson sold 10,725 shares of the company’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $47.39, for a total value of $508,257.75. Following the transaction, the director now directly owns 15,845 shares in the company, valued at $750,894.55. The disclosure for this sale can be found here. Insiders have sold 88,725 shares of company stock worth $4,459,085 over the last ninety days. 6.57% of the stock is owned by insiders.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.